Evidence for Residual Immunity to Smallpox After Vaccination and Implications for Re-emergence.


Journal

Military medicine
ISSN: 1930-613X
Titre abrégé: Mil Med
Pays: England
ID NLM: 2984771R

Informations de publication

Date de publication:
01 12 2019
Historique:
received: 26 11 2018
revised: 22 02 2019
accepted: 27 06 2019
pubmed: 2 8 2019
medline: 8 8 2020
entrez: 2 8 2019
Statut: ppublish

Résumé

Smallpox has been eradicated but advances in synthetic biology have increased the risk of its re-emergence. Residual immunity in individuals who were previously vaccinated may mitigate the impact of an outbreak, but there is a high degree of uncertainty about the duration and degree of residual immunity. Both cell-mediated and humoral immunity are thought to be important but the exact mechanisms of protection are unclear. Guidelines usually suggest vaccine-induced immunity wanes to zero after 3-10 years post vaccination, whereas other estimates show long term immunity over decades. A systematic review of the literature was conducted to quantify the duration and extent of residual immunity to smallpox after vaccination. Twenty-nine papers related to quantifying residual immunity to smallpox after vaccination were identified: neutralizing antibody levels were used as immune correlates of protection in 11/16 retrospective cross-sectional studies, 2/3 epidemiological studies, 6/7 prospective vaccine trials and 0/3 modeling studies. Duration of protection of >20 years was consistently shown in the 16 retrospective cross-sectional studies, while the lowest estimated duration of protection was 11.7 years among the modeling studies. Childhood vaccination conferred longer duration of protection than vaccination in adulthood, and multiple vaccinations did not appear to improve immunity. Most studies suggest a longer duration of residual immunity (at least 20 years) than assumed in smallpox guidelines. Estimates from modeling studies were less but still greater than the 3-10 years suggested by the WHO Committee on International Quarantine or US CDC guidelines. These recommendations were probably based on observations and studies conducted while smallpox was endemic. The cut-off values for pre-existing antibody levels of >1:20 and >1:32 reported during the period of endemic smallpox circulation may not be relevant to the contemporary population, but have been used as a threshold for identifying people with residual immunity in post-eradication era studies. Of the total antibodies produced in response to smallpox vaccination, neutralizing antibodies have shown to contribute significantly to immunological memory. Although the mechanism of immunological memory and boosting is unclear, revaccination is likely to result in a more robust response. There is a need to improve the evidence base for estimates on residual immunity to better inform planning and preparedness for re-emergent smallpox.

Identifiants

pubmed: 31369103
pii: 5542515
doi: 10.1093/milmed/usz181
doi:

Substances chimiques

Smallpox Vaccine 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e668-e679

Informations de copyright

© Association of Military Surgeons of the United States 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Mohana Priya Kunasekaran (MP)

Kirby Institute, Faculty of Medicine, University of New South Wales, Australia.

Xin Chen (X)

Kirby Institute, Faculty of Medicine, University of New South Wales, Australia.

Valentina Costantino (V)

Kirby Institute, Faculty of Medicine, University of New South Wales, Australia.

Abrar Ahmad Chughtai (AA)

School of Public Health and Community Medicine, Faculty of Medicine, University of New South Wales, Australia.

Chandini Raina MacIntyre (CR)

Kirby Institute, Faculty of Medicine, University of New South Wales, Australia.
College of Public Service and Community Solutions, Arizona State University, AZ.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH